Anti-HER3 therapeutics are currently under investigation in Phase 1/2 clinical trials for treatment of different breast cancer subtypes, including HR + /HER2- [21], HER2+ [22] and TNBC (NCT05057013). Here, ERBB2 is linked to breast cancer.